Antibody Subclass and Glycosylation Shift Following Effective TB Treatment
<jats:p>With an estimated 25% of the global population infected with <jats:italic>Mycobacterium tuberculosis</jats:italic> (<jats:italic>Mtb</jats:italic>), tuberculosis (TB) remains a leading cause of death by infectious diseases. Humoral immunity following TB treatmen...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media SA
2021
|
| Online Access: | https://hdl.handle.net/1721.1/136134 |
| _version_ | 1826208459236835328 |
|---|---|
| author | Grace, Patricia S Dolatshahi, Sepideh Lu, Lenette L Cain, Adam Palmieri, Fabrizio Petrone, Linda Fortune, Sarah M Ottenhoff, Tom HM Lauffenburger, Douglas A Goletti, Delia Joosten, Simone A Alter, Galit |
| author_facet | Grace, Patricia S Dolatshahi, Sepideh Lu, Lenette L Cain, Adam Palmieri, Fabrizio Petrone, Linda Fortune, Sarah M Ottenhoff, Tom HM Lauffenburger, Douglas A Goletti, Delia Joosten, Simone A Alter, Galit |
| author_sort | Grace, Patricia S |
| collection | MIT |
| description | <jats:p>With an estimated 25% of the global population infected with <jats:italic>Mycobacterium tuberculosis</jats:italic> (<jats:italic>Mtb</jats:italic>), tuberculosis (TB) remains a leading cause of death by infectious diseases. Humoral immunity following TB treatment is largely uncharacterized, and antibody profiling could provide insights into disease resolution. Here we focused on the distinctive TB-specific serum antibody features in active TB disease (ATB) and compared them with latent TB infection (LTBI) or treated ATB (txATB). As expected, di-galactosylated glycan structures (lacking sialic acid) found on IgG-Fc differentiated LTBI from ATB, but also discriminated txATB from ATB. Moreover, TB-specific IgG4 emerged as a novel antibody feature that correlated with active disease, elevated in ATB, but significantly diminished after therapy. These findings highlight 2 novel TB-specific antibody changes that track with the resolution of TB and may provide key insights to guide TB therapy.</jats:p> |
| first_indexed | 2024-09-23T14:06:00Z |
| format | Article |
| id | mit-1721.1/136134 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T14:06:00Z |
| publishDate | 2021 |
| publisher | Frontiers Media SA |
| record_format | dspace |
| spelling | mit-1721.1/1361342021-10-28T03:42:36Z Antibody Subclass and Glycosylation Shift Following Effective TB Treatment Grace, Patricia S Dolatshahi, Sepideh Lu, Lenette L Cain, Adam Palmieri, Fabrizio Petrone, Linda Fortune, Sarah M Ottenhoff, Tom HM Lauffenburger, Douglas A Goletti, Delia Joosten, Simone A Alter, Galit <jats:p>With an estimated 25% of the global population infected with <jats:italic>Mycobacterium tuberculosis</jats:italic> (<jats:italic>Mtb</jats:italic>), tuberculosis (TB) remains a leading cause of death by infectious diseases. Humoral immunity following TB treatment is largely uncharacterized, and antibody profiling could provide insights into disease resolution. Here we focused on the distinctive TB-specific serum antibody features in active TB disease (ATB) and compared them with latent TB infection (LTBI) or treated ATB (txATB). As expected, di-galactosylated glycan structures (lacking sialic acid) found on IgG-Fc differentiated LTBI from ATB, but also discriminated txATB from ATB. Moreover, TB-specific IgG4 emerged as a novel antibody feature that correlated with active disease, elevated in ATB, but significantly diminished after therapy. These findings highlight 2 novel TB-specific antibody changes that track with the resolution of TB and may provide key insights to guide TB therapy.</jats:p> 2021-10-27T20:30:59Z 2021-10-27T20:30:59Z 2021 2021-09-07T16:26:52Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/136134 en 10.3389/fimmu.2021.679973 Frontiers in Immunology Creative Commons Attribution 4.0 International license https://creativecommons.org/licenses/by/4.0/ application/pdf Frontiers Media SA Frontiers |
| spellingShingle | Grace, Patricia S Dolatshahi, Sepideh Lu, Lenette L Cain, Adam Palmieri, Fabrizio Petrone, Linda Fortune, Sarah M Ottenhoff, Tom HM Lauffenburger, Douglas A Goletti, Delia Joosten, Simone A Alter, Galit Antibody Subclass and Glycosylation Shift Following Effective TB Treatment |
| title | Antibody Subclass and Glycosylation Shift Following Effective TB Treatment |
| title_full | Antibody Subclass and Glycosylation Shift Following Effective TB Treatment |
| title_fullStr | Antibody Subclass and Glycosylation Shift Following Effective TB Treatment |
| title_full_unstemmed | Antibody Subclass and Glycosylation Shift Following Effective TB Treatment |
| title_short | Antibody Subclass and Glycosylation Shift Following Effective TB Treatment |
| title_sort | antibody subclass and glycosylation shift following effective tb treatment |
| url | https://hdl.handle.net/1721.1/136134 |
| work_keys_str_mv | AT gracepatricias antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment AT dolatshahisepideh antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment AT lulenettel antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment AT cainadam antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment AT palmierifabrizio antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment AT petronelinda antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment AT fortunesarahm antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment AT ottenhofftomhm antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment AT lauffenburgerdouglasa antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment AT golettidelia antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment AT joostensimonea antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment AT altergalit antibodysubclassandglycosylationshiftfollowingeffectivetbtreatment |